An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease

被引:34
作者
Haslam, N [1 ]
Standen, GR [1 ]
Probert, CS [1 ]
机构
[1] Gloucestershire Royal Hosp, Dept Gastroenterol, Gloucester GL1 3NN, England
关键词
factor V Leiden; inflammatory bowel disease; thrombosis;
D O I
10.1097/00042737-199911000-00018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A thrombotic aetiology for inflammatory bowel disease (IBD) has been proposed as a result of its association with thrombo-embolic complications, smoking, the oral contraceptive pill and the response of ulcerative colitis (UC) patients to heparin. The factor V Leiden (FVL) mutation is the commonest inherited risk factor for thrombo-embolism. Aim The aim of the study was to investigate the hypothesis that the pro-thrombotic state associated with the FVL mutation is involved in the aetiology of IBD. Patients and methods A prospective cohort study of patients attending the Bristol Royal Infirmary IBD outpatient clinic was performed, Fifty-four patients with IBD (30 with Crohn's disease (CD) and 24 with UC) and 55 historical controls were screened for the presence of FVL using the activated protein C (APC) ratio. Abnormal APC ratios were confirmed to be due to NL using a heteroduplex-based polymerase chain reaction (PCR) technique. Results Five patients had the FVL mutation, compared to two controls. One of the patients was homozygous. Two of the patients had CD and three UC. The differences between controls and IBD patients was significant when the allelic frequency of the FVL mutation in patients with UC was compared with controls, with a risk ratio of 2.27, but with limited data. Conclusion There appears to be a weak association between FVL and UC. This association is not strong enough to imply a causal relationship, but may be responsible for some of the thrombo-embolic complications. Eur J Gastroenterol Hepatol 11:1289-1291 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1289 / 1291
页数:3
相关论文
共 16 条
[1]  
BENINI C, 1984, SCAND J GASTROENTERO, V19, P824
[2]  
Bowen DJ, 1997, THROMB HAEMOSTASIS, V77, P119
[3]  
CANCHIS PW, 1993, IMMUNOLOGY, V80, P1
[4]  
GAFFNEY PR, 1995, AM J GASTROENTEROL, V90, P220
[5]  
Heneghan MA, 1998, DIGEST DIS SCI, V43, P1356
[6]   Activated protein C resistance: From phenotype to genotype and clinical practice [J].
Hillarp, A ;
Dahlback, B ;
Zoller, B .
BLOOD REVIEWS, 1995, 9 (04) :201-212
[7]   Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and Factor V Leiden [J].
Jackson, LM ;
OGorman, PJ ;
OConnell, J ;
Cronin, CC ;
Cotter, KP ;
Shanahan, F .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (03) :183-188
[8]   EVIDENCE FOR AN INCREASED RISK OF CROHNS-DISEASE IN ORAL-CONTRACEPTIVE USERS [J].
LESKO, SM ;
KAUFMAN, DW ;
ROSENBERG, L ;
HELMRICH, SP ;
MILLER, DR ;
STOLLEY, PD ;
SHAPIRO, S .
GASTROENTEROLOGY, 1985, 89 (05) :1046-1049
[9]   Activated protein C resistance in pediatric inflammatory bowel disease [J].
Levine, A ;
Lahav, J ;
Zahavi, I ;
Raz, A ;
Dinari, G .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1998, 26 (02) :172-174
[10]  
LEVINE JB, 1995, GASTROENTEROL CLIN N, V24, P633